Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000594073 | SCV000700374 | uncertain significance | not provided | 2018-05-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000766037 | SCV000897476 | uncertain significance | Infantile nephronophthisis | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001242893 | SCV001416012 | uncertain significance | Nephronophthisis | 2022-11-01 | criteria provided, single submitter | clinical testing | This sequence change replaces glutamine, which is neutral and polar, with glutamic acid, which is acidic and polar, at codon 796 of the INVS protein (p.Gln796Glu). This variant is present in population databases (rs147731667, gnomAD 0.2%). This variant has not been reported in the literature in individuals affected with INVS-related conditions. ClinVar contains an entry for this variant (Variation ID: 496840). Algorithms developed to predict the effect of missense changes on protein structure and function (SIFT, PolyPhen-2, Align-GVGD) all suggest that this variant is likely to be tolerated. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Prevention |
RCV003962658 | SCV004782736 | likely benign | INVS-related condition | 2022-02-12 | criteria provided, single submitter | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |